Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- F-3ASR Automatic shelf registration (foreign)
- 4.3 Form of Senior Teva Pharmaceutical Industries Limited Indenture
- 4.4 Form of Guaranteed Senior Finance Subsidiary Indenture
- 4.5 Form of Subordinated Teva Pharmaceutical Industries Limited Indenture
- 4.6 Form of Guaranteed Subordinated Finance Subsidiary Indenture
- 5.1 Opinion of Tulchinsky Stern Marciano Cohen Levitski & Co (Israeli Law)
- 5.2 Opinion of Willkie Farr & Gallagher LLP (New York Law)
- 5.3 Opinion of Vaneps Kunneman Vandoorne (Curacao Law)
- 12.1 Statement Re Computation of Consolidated Ratio of Earnings to Fixed Charges
- 23.1 Consent of Kesselman & Kesselman
- 25.1 Statement of Eligibility of the Bank of New York Mellon, Senior Indenture
- 25.2 Statement of Eligibility of the Bank of New York Mellon, Subordinated Indenture
- 25.3 Statement of Eligibility of the Bank of New York Mellon, Senior Indenture
- 25.4 Statement of Eligibility of the Bank of New York Mellon, Subordinated Indenture
- 25.5 Statement of Eligibility of the Bank of New York Mellon, Senior Indenture
- 25.6 Statement of Eligibility of the Bank of New York Mellon, Subordinated Indenture
- 25.7 Statement of Eligibility of the Bank of New York Mellon, Senior Indenture
- 25.8 Statement of Eligibility of the Bank of New York Mellon, Subordinated Indenture
- 25.9 Statement of Eligibility of the Bank of New York Mellon, Senior Indenture
- 25.10 Statement of Eligibility of the Bank of New York Mellon, Subordinated Indenture
- 25.11 Statement of Eligibility of the Bank of New York Mellon, Senior Indenture
- 25.12 Statement of Eligibility of the Bank of New York Mellon, Subordinated Indenture
- 25.13 Statement of Eligibility of the Bank of New York Mellon, Senior Indenture
- 25.14 Statement of Eligibility of the Bank of New York Mellon, Subordinated Indenture
- 25.15 Statement of Eligibility of the Bank of New York Mellon, Senior Indenture
- 25.16 Statement of Eligibility of the Bank of New York Mellon, Subordinated Indenture
- 25.17 Statement of the Bank of New York Mellon, Senior Indenture
- 25.18 Statement of Eligibility of the Bank of New York Mellon, Subordinated Indenture
- 25.19 Statement of Eligibility of the Bank of New York Mellon, Senior Indenture
- 25.20 Statement of Eligibility of the Bank of New York Mellon, Subordinated Indenture
Teva Pharmaceutical Finance Iii BV similar filings
Filing view
External links
Exhibit 12.1
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
Nine Months Ended September | Year Ended December 31, | |||||||||||||||||||||||
30, 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||||||||||||||||||
(U.S. dollars in millions, except ratios) | ||||||||||||||||||||||||
Earnings | ||||||||||||||||||||||||
Pre-tax income from continuing operations before adjustments for minority interests in consolidated subsidiaries or income or loss from equity investments | 2,413.48 | 3,646.11 | 2,203.06 | 800.00 | 2,304.00 | 664.00 | ||||||||||||||||||
Fixed charges, as below | 159.83 | 234.93 | 262.80 | 226.61 | 271.42 | 216.98 | ||||||||||||||||||
Interest capitalized, less amortization of capitalized interest | (3.53 | ) | — | — | — | — | — | |||||||||||||||||
Total | 2,569.78 | 3,881.07 | 2,465.86 | 1,026.61 | 2,575.42 | 880.98 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Fixed Charges | ||||||||||||||||||||||||
Interest costs (expensed and capitalized) and amortization of issuance costs relating to long term debentures | 134.54 | 203.21 | 232.48 | 205.87 | 254.51 | 204.36 | ||||||||||||||||||
Rentals – one third of rental expenses | 25.30 | 31.75 | 30.32 | 20.74 | 16.91 | 12.62 | ||||||||||||||||||
Total | 159.83 | 234.96 | 262.80 | 226.61 | 271.42 | 216.98 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Ratio of Earnings to Fixed Charges | 16.1 | 16.5 | 9.4 | 4.5 | 9.5 | 4.1 |